{"entity":{"type":"insider","cik":"0001491847","url":"/insider/0001491847","json_url":"/insider/0001491847.json","name":"Oki Mark K","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":6,"first":"2012-06-08","last":"2025-09-22","span_basis":"filed_date"},"name_variants":[{"name":"Oki Mark K","source":"filing","n_filings":6,"first_seen":"2012-06-08","last_seen":"2025-09-22"}],"transactions":[{"id":4092893,"accession":"0001193125-25-211404","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-211404","line_url":"/filing/0001193125-25-211404#line-2","is_derivative":false,"issuer_cik":"0000949858","issuer_name":"ACHIEVE LIFE SCIENCES, INC.","issuer_ticker":"ACHV","issuer_name_source":null,"issuer_url":"/issuer/0000949858","owner_cik":"0001491847","owner_name":"Oki Mark K","owner_display_name":"Oki Mark K","owner_url":"/insider/0001491847","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50060.0,"shares_display":"50,060","price_per_share":2.92,"price_display":"2.92","price_state":"stated","total_value":146175.2,"total_display":"146,175.20","total_whole":"146,175","shares_owned_after":127940.0,"shares_owned_after_display":"127,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-18","filed_date":"2025-09-22","scope":"insider"},{"id":4712844,"accession":"0000950170-25-042074","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-042074","line_url":"/filing/0000950170-25-042074#line-1","is_derivative":false,"issuer_cik":"0000949858","issuer_name":"ACHIEVE LIFE SCIENCES, INC.","issuer_ticker":"ACHV","issuer_name_source":null,"issuer_url":"/issuer/0000949858","owner_cik":"0001491847","owner_name":"Oki Mark K","owner_display_name":"Oki Mark K","owner_url":"/insider/0001491847","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":2.8887,"price_display":"2.89","price_state":"stated","total_value":28887.0,"total_display":"28,887.00","total_whole":"28,887","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-17","filed_date":"2025-03-19","scope":"insider"},{"id":9292182,"accession":"0001567619-22-020920","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-020920","line_url":"/filing/0001567619-22-020920#line-1","is_derivative":false,"issuer_cik":"0001385818","issuer_name":"AYTU BIOPHARMA, INC","issuer_ticker":"AYTU","issuer_name_source":null,"issuer_url":"/issuer/0001385818","owner_cik":"0001491847","owner_name":"Oki Mark K","owner_display_name":"Oki Mark K","owner_url":"/insider/0001491847","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90000.0,"shares_display":"90,000","price_per_share":0.23,"price_display":"0.23","price_state":"stated","total_value":20700.0,"total_display":"20,700.00","total_whole":"20,700","shares_owned_after":190000.0,"shares_owned_after_display":"190,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-18","filed_date":"2022-11-28","scope":"insider"},{"id":6622320,"accession":"0001123292-18-001056","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001123292-18-001056","line_url":"/filing/0001123292-18-001056#line-1","is_derivative":false,"issuer_cik":"0000881524","issuer_name":"VIVUS INC","issuer_ticker":"VVUS","issuer_name_source":null,"issuer_url":"/issuer/0000881524","owner_cik":"0001491847","owner_name":"Oki Mark K","owner_display_name":"Oki Mark K","owner_url":"/insider/0001491847","role":"Officer (Chief Financial Officer & CAO)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer & CAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer & CAO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":4.07,"price_display":"4.07","price_state":"stated","total_value":40700.0,"total_display":"40,700.00","total_whole":"40,700","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-06","filed_date":"2018-11-07","scope":"insider"},{"id":3398674,"accession":"0001209191-12-043655","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-043655","line_url":"/filing/0001209191-12-043655#line-1","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001491847","owner_name":"Oki Mark K","owner_display_name":"Oki Mark K","owner_url":"/insider/0001491847","role":"Officer (SVP, CFO and Sec)","role_mark":"O","role_mark_label":"Officer (SVP, CFO and Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CFO and Sec","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":4.1364,"price_display":"4.14","price_state":"stated","total_value":41364.0,"total_display":"41,364.00","total_whole":"41,364","shares_owned_after":3788.0,"shares_owned_after_display":"3,788","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-08-27","filed_date":"2012-08-29","scope":"insider"},{"id":3501299,"accession":"0001209191-12-033058","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-033058","line_url":"/filing/0001209191-12-033058#line-1","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001491847","owner_name":"Oki Mark K","owner_display_name":"Oki Mark K","owner_url":"/insider/0001491847","role":"Officer (VP Fin Controller PAO PFO Sec)","role_mark":"O","role_mark_label":"Officer (VP Fin Controller PAO PFO Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Fin Controller PAO PFO Sec","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31873.0,"shares_display":"31,873","price_per_share":0.3381,"price_display":"0.34","price_state":"stated","total_value":10776.2613,"total_display":"10,776.26","total_whole":"10,776","shares_owned_after":137896.0,"shares_owned_after_display":"137,896","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-06-06","filed_date":"2012-06-08","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":6,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":3,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":6},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000949858","name":"ACHIEVE LIFE SCIENCES, INC.","url":"/issuer/0000949858","role":"Officer (Chief Financial Officer)","n_filings":2,"first_seen":"2025-03-19","last_seen":"2025-09-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001385818","name":"AYTU BIOPHARMA, INC","url":"/issuer/0001385818","role":"Officer (Chief Financial Officer)","n_filings":1,"first_seen":"2022-11-28","last_seen":"2022-11-28"},{"type":"issuer","type_label":"ISSUER","cik":"0000881524","name":"VIVUS INC","url":"/issuer/0000881524","role":"Officer (Chief Financial Officer & CAO)","n_filings":1,"first_seen":"2018-11-07","last_seen":"2018-11-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001344413","name":"Alexza Pharmaceuticals Inc.","url":"/issuer/0001344413","role":"Officer (SVP, CFO and Sec)","n_filings":2,"first_seen":"2012-06-08","last_seen":"2012-08-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001491847","retrieved_at":"2026-08-25T04:58:25+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}